⌘K
Loading ticker…
Spyre Therapeutics, Inc. Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, Spyre Therapeutics, Inc. Common Stock (SYRE) has a 3-month relative strength percentile of 95 and a leadership percentile of 96 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 97. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 6.4%, relative volume 2.82×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
3m RS is 95, Market Stance is mixed at 47, A/D rating C
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
SYRE is in a stage 2 uptrend, week 12. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 15.7% / 105.5%.
No attention data for this ticker yet — it joins the daily scan once a baseline builds.
SYRE is held by 6 ETFs as of Mar 2026. Top owner: VTI at 0.01% weight, $112M notional. Top 3 carry $251M.
Top 6 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.01% | $112M |
| IWMiShares Russell 2000 ETF | 0.12% | $85M |
| XBIState Street SPDR S&P Biotech ETF | 0.73% | $54M |
| VXFVanguard Extended Market ETF | 0.05% | $38M |
| IWOiShares Russell 2000 Growth ETF | 0.16% | $19M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.01% | $5M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | SYRE Jan avg: 5.59% median: -1.25% win: 33% σ: 12.84% n: 3 2023-11-29 → 2026-05-29 | SYRE Feb avg: 8.70% median: 5.91% win: 67% σ: 24.52% n: 3 2023-11-29 → 2026-05-29 | SYRE Mar avg: 12.47% median: 17.27% win: 67% σ: 28.47% n: 3 2023-11-29 → 2026-05-29 | SYRE Apr avg: 9.69% median: -5.61% win: 33% σ: 33.03% n: 3 2023-11-29 → 2026-05-29 | SYRE May avg: 1.62% median: 0.33% win: 67% σ: 3.72% n: 3 2023-11-29 → 2026-05-29 | SYRE Jun avg: -17.38% median: -17.38% win: 0% σ: 21.71% n: 2 2023-11-29 → 2026-05-29 (current) | SYRE Jul avg: 15.17% median: 15.17% win: 100% σ: 2.55% n: 2 2023-11-29 → 2026-05-29 | SYRE Aug avg: 0.86% median: 0.86% win: 50% σ: 5.21% n: 2 2023-11-29 → 2026-05-29 | SYRE Sep avg: 1.97% median: 1.97% win: 100% σ: 0.46% n: 2 2023-11-29 → 2026-05-29 | SYRE Oct avg: 28.28% median: 28.28% win: 100% σ: 24.98% n: 2 2023-11-29 → 2026-05-29 | SYRE Nov avg: 12.91% median: 22.65% win: 67% σ: 22.30% n: 3 2023-11-29 → 2026-05-29 | SYRE Dec avg: 2.14% median: 9.20% win: 67% σ: 17.80% n: 3 2023-11-29 → 2026-05-29 |